ResearcherHôpital BeaujonNo recent work listed

Michele Lamuraglia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8009-0218; OpenAlex author ID A5085728469. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper

Papers 2

PARP inhibition in treatment of pancreatic cancer. Last author DOI 10.1080/14737140.2020.1820330 ↗
Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for er… Co-author DOI 10.21037/hbsn.2018.08.03 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Pascal R. Hammel · 2 shared papers, 2018–2020 · strength 0.20
- Paper PARP inhibition in treatment of pancreatic cancer. DOI 10.1080/14737140.2020.1820330 ↗
- Paper Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ducta… DOI 10.21037/hbsn.2018.08.03 ↗
Jerome F. Cros · 1 shared paper, 2020 · strength 0.11
- Paper PARP inhibition in treatment of pancreatic cancer. DOI 10.1080/14737140.2020.1820330 ↗
Louis de Mestier · 1 shared paper, 2020 · strength 0.11
- Paper PARP inhibition in treatment of pancreatic cancer. DOI 10.1080/14737140.2020.1820330 ↗
Mathilde Wisniewski · 1 shared paper, 2018 · strength 0.09
- Paper Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ducta… DOI 10.21037/hbsn.2018.08.03 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.